United Therapeutics Corporation/ US91307C1027 /
| 11/8/2024 10:00:00 PM | Chg. +7.4300 | Volume | Bid12:55:50 AM | Ask12:55:50 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 410.0000USD | +1.85% | 498,743 Turnover: 117.86 mill. |
339.1000Bid Size: 100 | 666.6500Ask Size: 200 | 18.3 bill.USD | - | 19.49 |
Assets
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | - | 366 | 453.7000 | 465 | 478.4210 | ||||||
| Intangible Assets | - | 22.1000 | 16.4000 | 14.1000 | - | ||||||
| Long-Term Investments | - | - | - | - | 122.7870 | ||||||
| Fixed Assets | - | - | - | - | - | ||||||
| Inventories | - | 46 | 37.3000 | 47.8000 | 66.9270 | ||||||
| Accounts Receivable | - | 88.7000 | 116.6000 | 126.3000 | 162.2870 | ||||||
| Cash and Cash Equivalents | - | 162.7000 | 154 | 278.9000 | 397.6970 | ||||||
| Current Assets | - | 562.5000 | 668.5000 | 909 | 974.1970 | ||||||
| Total Assets | - | 1,518.1000 | 1,626.6000 | 2,087.6000 | 1,884.4100 | ||||||
Liabilities
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | 47.3000 | 10.2000 | 0.0000 | - | ||||||
| Long-term debt | - | 71.5000 | 70.3000 | 3.7000 | - | ||||||
| Liabilities to Banks | - | 71.5000 | 70.3000 | 3.7000 | 0.0000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | - | 558.7000 | 531.7000 | 783.3000 | 642.0540 | ||||||
| Share Capital | - | .6150 | .6210 | .6300 | .6600 | ||||||
| Total Equity | - | 959.4000 | 1,094.9000 | 1,304.3000 | 1,242.3560 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | - | 1,518.1000 | 1,626.6000 | 2,087.6000 | 1,884.4100 | ||||||
Income Statement
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 592.9000 | 743.2000 | 916.1000 | 1,117 | 1,288.5190 | ||||||
| Depreciation (total) | - | - | - | - | 32.2450 | ||||||
| Operating Result | 171.3000 | 317.8000 | 421.6000 | 292.5000 | 538.8000 | ||||||
| Interest Income | -16.8000 | -17.9000 | -12.7000 | -14.3000 | -17.5920 | ||||||
| Income Before Taxes | 155.2000 | 299.1000 | 440.7000 | 278.9000 | 525.1800 | ||||||
| Income Taxes | 44 | 81.9000 | 136.2000 | 104.3000 | -185.1060 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 105.9000 | 217.9000 | 304.4000 | 174.6000 | 340.0740 | ||||||
Per Share
Cash Flow
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 211.5000 | 250.2000 | 323.6000 | 425.3000 | 355.2590 | ||||||
| Cash Flow from Investing Activities | -209.2000 | -121.3000 | -163.4000 | -295 | 338.4650 | ||||||
| Cash Flow from Financing | 146.8000 | -218.1000 | -169.1000 | -5.1000 | -576.5350 | ||||||
| Decrease / Increase in Cash | 151.8000 | -89.5000 | -8.6000 | 124.9000 | 113.4390 | ||||||
| Employees | 520 | 543 | 623 | 706 | 740 | ||||||
